デスモイド腫瘍市場：治療タイプ、薬剤タイプ、腫瘍部位、エンドユーザー、年齢層別-2025-2030年の世界予測

デスモイド腫瘍市場は、2023年に25億4,000万米ドルと評価され、2024年には26億8,000万米ドル、CAGR 5.88%で成長し、2030年には37億9,000万米ドルに達すると予測されています。

デスモイド腫瘍の世界の状況は、急速な臨床進化と多角的な治療アプローチに対する需要の増加を特徴としています。新たな調査、新たな治療法、そしてこの疾患の遺伝的特性に対する理解の深まりが、市場力学を決定的に形成しています。近年、臨床医と利害関係者は、患者管理と治療法の戦略的展開の両面で進化を目の当たりにしています。新しい診断技術や画像診断法の改善は早期発見に寄与し、患者の転帰を改善します。規制の枠組みが進化し、精密医療への需要が高まる中、この分野の専門家は、戦略の指針となる高度な調査データと治療イノベーションへの依存度を高めています。このイントロダクションでは、市場勢力、臨床試験、進化する治療プロトコールが、統合戦略の必要性をどのように促してきたかを概観します。続くセクションを深く読み進めていくと、これらの重要な要因が、デスモイド腫瘍の治療において、市場への浸透、規制への適応、ヘルスケア全般への影響にどのように収束していくかを見分けることができると思われます。この分野での進歩は、疾患に対する理解を深めるだけでなく、医療システムにオーダーメイドのアプローチを採用する力を与え、最終的に患者のケアと転帰を改善します。

市場情勢を形成する変革的変化

過去10年間、デスモイド腫瘍市場は、技術革新と規制の再編成の両方が新たな治療パラダイムの舞台を整え、変革的な変化を経験してきました。最先端の診断ツールの導入により、腫瘍発見のタイミングと精度が加速され、精密医療が極めて重要な役割を果たす段階が到来しました。さらに、デジタルヘルスプラットフォームとデータ分析の統合により、臨床医は微妙な患者プロファイルに基づいて治療レジメンを個別化できるようになり、臨床転帰の改善につながりました。市場関係者は現在、人工知能と機械学習の進歩を活用して治療反応を予測し、ヘルスケア提供を最適化しています。さらに、最近の規制環境の変化により、医薬品の承認プロセスを促進するための枠組みが整備され、研究開発への投資が活発化しています。このような多面的な発展は、競争力のあるイノベーションを刺激するだけでなく、世界中の主要な利害関係者間のコラボレーションを促しています。このような環境の進化により、科学的なブレークスルーが患者を中心とした実用的な治療ソリューションに迅速に変換されるようになり、デスモイド腫瘍との戦いにおける治療経路の構想や実施方法が根本的に変革されています。

市場セグメンテーションに関する重要な洞察

市場を深く評価することで、デスモイド腫瘍治療の戦略的意思決定の指針となる洞察に満ちたセグメンテーションが明らかになります。治療タイプに基づく分析では、抗ホルモン療法、化学療法、冷凍アブレーション、非ステロイド性抗炎症薬、放射線療法、手術、標的療法など、多様な治療状況が明らかになります。抗ホルモン療法では、タモキシフェンやトレミフェンなどの薬剤をさらに精査することで、微妙な治療成績が明らかになり、化学療法では、ドキソルビシンベースの治療、メトトレキサートとビンブラスチンを含む併用療法、ペグ化リポソームドキソルビシンの使用などのレジメンに分解されます。セグメンテーションは薬剤の種類にまで及び、市販薬と処方薬とが明確に区別され、入手しやすさと規制監督における根本的な格差が強調されています。腫瘍部位のセグメンテーションは、腹部、腹外、腹腔内などの解剖学的分類の意味を明らかにし、外来手術センター、病院、専門クリニックなどのエンドユーザーは流通モデルを決定します。さらに、成人、老年、小児の各年齢層で患者ケアを区別する年齢層セグメンテーションによって、さらなる洞察が提供されます。各セグメンテーション・パラメータは、市場成長と患者管理の最適化のためのテーラーメイド戦略をサポートするきめ細かいビューを提供します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • デスモイド腫瘍の罹患率の上昇が臨床調査投資の急増に貢献している
    • デスモイド腫瘍に関する意識と教育の向上は、早期診断と介入につながる
  • 抑制要因
    • デスモイド腫瘍の症状の大きな異質性が治療の標準化を複雑化させる
  • 機会
    • デスモイド腫瘍の管理における個別化治療戦略のための精密医療イニシアチブの活用
    • デスモイド腫瘍切除における低侵襲手術技術の成長ポテンシャルの評価
  • 課題
    • 転移性がなく希少なため治療選択肢が限られていることに対処する
• 市場セグメンテーション分析
  • 治療の種類：腫瘍の再発を防ぐため、手術後に放射線療法を利用する
  • 薬物の種類：デスモイド腫瘍における標的を定めた持続的な治療介入のための処方薬の使用
  • 腫瘍の位置：腹腔外デスモイド腫瘍への放射線療法の採用は侵襲性のためである
  • エンドユーザー：腫瘍切除が簡単なため、外来手術センターの選好度が高まっている
  • 年齢層：加齢に伴う要因や併存疾患により成人で増加しているデスモイド腫瘍
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 デスモイド腫瘍市場治療の種類別

• 抗ホルモン療法
  • タモキシフェン
  • トレミフェン
• 化学療法
  • ドキソルビシンベースのレジメン
  • メトトレキサートとビンブラスチン
  • ペグ化リポソームドキソルビシン
• 凍結療法
• 非ステロイド性抗炎症薬（NSAID）
• 放射線治療
• 手術
• 標的療法

第7章 デスモイド腫瘍市場薬剤の種類別

• 市販薬
• 処方薬

第8章 デスモイド腫瘍市場腫瘍の位置別

• 腹部
• 腹部外
• 腹腔内

第9章 デスモイド腫瘍市場：エンドユーザー別

• 外来手術センター
• 病院
• 専門クリニック

第10章 デスモイド腫瘍市場：年齢層別

• 成人用
• 高齢者
• 小児科

第11章 南北アメリカのデスモイド腫瘍市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のデスモイド腫瘍市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのデスモイド腫瘍市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Apotex Inc.
• Baxter International, Inc
• Bayer AG
• Bristol-Myers Squibb Company
• Cipla Limited
• Dr Reddys Laboratories Limited
• Encapsula NanoSciences LLC
• Fermion Oy by Orion Corporation
• Hetero Healthcare Limited.
• Immunome, Inc.
• Intelicure Lifesciences
• Iterion Therapeutics
• Johnson & Johnson Services, Inc.
• Mayne Pharma Group Limited
• Medichem, S.A.
• Natco Pharma Limited
• Novartis AG
• Pfizer Inc.
• SpringWorks Therapeutics, Inc.
• Sun Pharmaceutical Industries Limited
• Synthon International Holding B.V.
• Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

• FIGURE 1. DESMOID TUMORS MARKET MULTI-CURRENCY
• FIGURE 2. DESMOID TUMORS MARKET MULTI-LANGUAGE
• FIGURE 3. DESMOID TUMORS MARKET RESEARCH PROCESS
• FIGURE 4. DESMOID TUMORS MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL DESMOID TUMORS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL DESMOID TUMORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES DESMOID TUMORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES DESMOID TUMORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. DESMOID TUMORS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. DESMOID TUMORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DESMOID TUMORS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DESMOID TUMORS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DESMOID TUMORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DESMOID TUMORS MARKET DYNAMICS
• TABLE 7. GLOBAL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DESMOID TUMORS MARKET SIZE, BY TAMOXIFEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DESMOID TUMORS MARKET SIZE, BY TOREMIFENE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DESMOID TUMORS MARKET SIZE, BY DOXORUBICIN-BASED REGIMENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DESMOID TUMORS MARKET SIZE, BY METHOTREXATE AND VINBLASTINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DESMOID TUMORS MARKET SIZE, BY PEGYLATED LIPOSOMAL DOXORUBICIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DESMOID TUMORS MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DESMOID TUMORS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DESMOID TUMORS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DESMOID TUMORS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DESMOID TUMORS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DESMOID TUMORS MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DESMOID TUMORS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DESMOID TUMORS MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DESMOID TUMORS MARKET SIZE, BY EXTRA-ABDOMINAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DESMOID TUMORS MARKET SIZE, BY INTRA-ABDOMINAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DESMOID TUMORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL DESMOID TUMORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL DESMOID TUMORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL DESMOID TUMORS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL DESMOID TUMORS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL DESMOID TUMORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 59. CANADA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CANADA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 61. CANADA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 62. CANADA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. CANADA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 64. CANADA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. CANADA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES DESMOID TUMORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 96. CHINA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 97. CHINA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 98. CHINA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 99. CHINA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. CHINA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 101. CHINA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. CHINA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 103. INDIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. INDIA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 105. INDIA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 106. INDIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 107. INDIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 108. INDIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. INDIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA DESMOID TUMORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 223. ITALY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 224. ITALY DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 225. ITALY DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 226. ITALY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 227. ITALY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 228. ITALY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 229. ITALY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 251. POLAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 252. POLAND DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 253. POLAND DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 254. POLAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 255. POLAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 256. POLAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 257. POLAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 258. QATAR DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 259. QATAR DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 260. QATAR DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 261. QATAR DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 262. QATAR DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 263. QATAR DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 264. QATAR DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 278. SAUDI ARABIA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 292. SPAIN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 299. SWEDEN DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 306. SWITZERLAND DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 312. TURKEY DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 313. TURKEY DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 319. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 320. UNITED ARAB EMIRATES DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY ANTI-HORMONAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
• TABLE 324. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 325. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY TUMOR LOCATION, 2018-2030 (USD MILLION)
• TABLE 326. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 327. UNITED KINGDOM DESMOID TUMORS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 328. DESMOID TUMORS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 329. DESMOID TUMORS MARKET, FPNV POSITIONING MATRIX, 2023

The Desmoid Tumors Market was valued at USD 2.54 billion in 2023 and is projected to grow to USD 2.68 billion in 2024, with a CAGR of 5.88%, reaching USD 3.79 billion by 2030.

The global landscape of desmoid tumors is characterized by rapid clinical evolution and an increasing demand for multidimensional treatment approaches. Emerging research, new treatment modalities, and a growing understanding of the disease's genetic attributes have critically shaped the market dynamics. In recent years, clinicians and stakeholders have witnessed an evolution in both patient management and the strategic deployment of therapies. Novel diagnostic techniques and improved imaging methods contribute to early detection, thereby facilitating better patient outcomes. Amid evolving regulatory frameworks and heightened demand for precision medicine, professionals in the field are increasingly relying on advanced research data and treatment innovation to guide strategy. This introduction provides an overview of how market forces, clinical trials, and evolving treatment protocols have driven the need for an integrated strategy. As you dive deeper into the ensuing sections, you will discern how these key factors converge to impact market penetration, regulatory adaptation, and overall healthcare delivery in treating desmoid tumors. The progress in this field not only enhances our understanding of the disease but also empowers health systems to adopt tailored approaches, ultimately improving patient care and outcomes.

Transformative Shifts Shaping Market Landscape

Over the past decade, the desmoid tumors market has experienced transformative shifts with both technological innovations and regulatory realignments setting the stage for new treatment paradigms. The infusion of cutting-edge diagnostic tools has accelerated the timing and accuracy of tumor detection, ushering in a phase where precision medicine plays a pivotal role. Furthermore, the integration of digital health platforms and data analytics has enabled clinicians to personalize therapy regimens based on nuanced patient profiles, resulting in improved clinical outcomes. Market players are now leveraging advancements in artificial intelligence and machine learning to predict treatment responses and optimize healthcare delivery. Additionally, recent changes in regulatory environments have provided a more conducive framework for accelerated drug approval processes, boosting investments in research and development. These multi-faceted developments not only stimulate competitive innovation but also invite collaboration between key stakeholders worldwide. This evolving environment ensures that scientific breakthroughs are rapidly translated into practical, patient-focused therapeutic solutions, fundamentally transforming how treatment pathways are conceived and implemented in the battle against desmoid tumors.

Critical Market Segmentation Insights

A deeper evaluation of the market reveals insightful segmentation that guides strategic decision-making for the treatment of desmoid tumors. Analysis based on treatment type uncovers a diverse therapeutic landscape including anti-hormonal therapy, chemotherapy, cryoablation, nonsteroidal anti-inflammatory drugs, radiation therapy, surgery, and targeted therapy. Within anti-hormonal therapy, further scrutiny of agents like tamoxifen and toremifene provides clarity on nuanced treatment outcomes, while chemotherapy is dissected into regimens such as doxorubicin-based treatments, combinations involving methotrexate and vinblastine, and the use of pegylated liposomal doxorubicin. The segmentation extends into drug types with clear differentiation between over-the-counter and prescription drugs, reinforcing the underlying disparities in accessibility and regulatory oversight. Tumor location segmentation elucidates the implications of anatomical classifications including abdominal, extra-abdominal, and intra-abdominal sites, whereas end users such as ambulatory surgical centers, hospitals, and specialty clinics determine distribution models. A further layer of insight is provided by the age group segmentation which differentiates patient care across adult, geriatric, and pediatric populations. Each segmentation parameter offers a granular view that supports tailored strategies for market growth and optimized patient management.

Based on Treatment Type, market is studied across Anti-Hormonal Therapy, Chemotherapy, Cryoablation, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Radiation Therapy, Surgery, and Targeted Therapy. The Anti-Hormonal Therapy is further studied across Tamoxifen and Toremifene. The Chemotherapy is further studied across Doxorubicin-based regimens, Methotrexate and Vinblastine, and Pegylated liposomal doxorubicin.

Based on Drug Type, market is studied across OTC Drugs and Prescription Drugs.

Based on Tumor Location, market is studied across Abdominal, Extra-Abdominal, and Intra-Abdominal.

Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.

Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.

Regional Market Variations and Trends

The geographic landscape of desmoid tumors treatment exhibits significant variations across key regions. In the Americas, a robust healthcare infrastructure combined with advanced technological integration has helped accelerate early detection and intervention processes. Meanwhile, regions in Europe, the Middle East, and Africa are witnessing a concerted effort toward harmonizing regulatory policies while simultaneously investing in advanced clinical research techniques. However, these areas face unique challenges such as economic disparities and varying levels of healthcare accessibility that influence market dynamics. In parallel, the Asia-Pacific region has experienced rapid growth owing to expanding healthcare infrastructures and increasing investments in biotechnological research. This region, in particular, demonstrates dynamic evolution in treatment protocols and clinical trial engagements, driven largely by a burgeoning middle class and supportive government initiatives. Cumulatively, these regional nuances not only spotlight the diversity in market penetration but also underline the necessity for region-specific strategies that encompass localized clinical practices, tailored regulatory pathways, and adaptive market entry strategies to address the unique challenges and opportunities in the desmoid tumors market.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Guiding Market Innovation

The competitive landscape of the desmoid tumors market is significantly shaped by the strategic initiatives of key global players. Industry leaders such as Apotex Inc., Baxter International, Inc, Bayer AG, and Bristol-Myers Squibb Company are leveraging their robust R&D capabilities and expansive distribution networks to reinforce their market positions. Organizations like Cipla Limited, Dr Reddys Laboratories Limited, and Encapsula NanoSciences LLC further underscore a commitment to innovation by developing novel therapeutic solutions tailored to complex clinical needs. Innovative companies including Fermion Oy by Orion Corporation and Hetero Healthcare Limited are actively engaging in breakthrough research that addresses unmet clinical needs associated with tumor treatment. Additional industry influencers such as Immunome, Inc., Intelicure Lifesciences, and Iterion Therapeutics are integrating advanced technologies into their treatment pipelines to deliver more precise and personalized therapeutic strategies. Collaboration and continuous evolution in their drug development and clinical trial processes have positioned these companies within the competitive framework. The strategic focus of industry pioneers like Johnson & Johnson Services, Inc., Mayne Pharma Group Limited, Medichem, S.A., Natco Pharma Limited, Novartis AG, Pfizer Inc., SpringWorks Therapeutics, Inc., Sun Pharmaceutical Industries Limited, Synthon International Holding B.V., and Teva Pharmaceutical Industries Ltd. further reinforces the emphasis on market leadership and innovation within this complex therapeutic area.

The report delves into recent significant developments in the Desmoid Tumors Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Baxter International, Inc, Bayer AG, Bristol-Myers Squibb Company, Cipla Limited, Dr Reddys Laboratories Limited, Encapsula NanoSciences LLC, Fermion Oy by Orion Corporation, Hetero Healthcare Limited., Immunome, Inc., Intelicure Lifesciences, Iterion Therapeutics, Johnson & Johnson Services, Inc., Mayne Pharma Group Limited, Medichem, S.A., Natco Pharma Limited, Novartis AG, Pfizer Inc., SpringWorks Therapeutics, Inc., Sun Pharmaceutical Industries Limited, Synthon International Holding B.V., and Teva Pharmaceutical Industries Ltd. Strategic Recommendations for Market Leadership

Drawing insights from the multifaceted market analysis, several actionable recommendations emerge for industry leaders striving to advance in the desmoid tumors arena. It is crucial to invest in nurturing partnerships with academic institutions and research organizations to promote collaboration in early drug discovery and clinical trials. Stakeholders should focus on enhancing data analytics capabilities to anticipate market trends and create predictive models that improve treatment outcomes. Modernizing patient care by integrating telemedicine and remote monitoring technologies could substantially streamline clinical processes. Furthermore, an emphasis on personalization of treatment plans-whether by leveraging detailed segmentation insights based on treatment types, drug classifications, anatomical tumor locations, end user profiles, or patient age groups-can drive targeted product development and improve market penetration. An agile approach to regulatory changes must also be considered, facilitating swift adaptation in regions facing evolving healthcare standards. Ultimately, a strategic emphasis on innovation, operational excellence, and market-specific customization will enable stronger competitive positioning and better patient outcomes within the rapidly evolving therapeutic landscape.

Conclusion & Future Outlook

In summary, the evolving landscape of desmoid tumors treatment reflects a dynamic convergence of clinical innovation, strategic market segmentation, and global regulatory adaptation. The unique interplay of technological advancements, region-specific intricacies, and the committed efforts of industry leaders has positioned the market for considerable growth in the coming years. Our analysis underscores that integrating tailored treatment protocols and embracing predictive analytics are imperative for modernizing therapeutic approaches. The collective contributions of cutting-edge pharmaceutical research and robust clinical trial outcomes pave the way for future industry evolution, ensuring improved patient care strategies. As market dynamics continue to shift, maintaining a competitive edge hinges on proactive adaptation to new regulatory frameworks and leveraging advanced technological innovations. Looking forward, stakeholders are well advised to focus on continuous research and collaborative engagements that drive both technological and therapeutic breakthroughs, thereby securing a forward-thinking, patient-centric market environment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence rates of desmoid tumors contributing to a surge in clinical research investments
    • 5.1.1.2. Increased awareness and education about desmoid tumors lead to early diagnosis and intervention
  • 5.1.2. Restraints
    • 5.1.2.1. Substantial heterogeneity in desmoid tumor presentation complicates treatment standardization
  • 5.1.3. Opportunities
    • 5.1.3.1. Leveraging precision medicine initiatives for personalized treatment strategies in desmoid tumor management
    • 5.1.3.2. Assessing the growth potential of minimally invasive surgical techniques for desmoid tumor excision
  • 5.1.4. Challenges
    • 5.1.4.1. Addressing the scarcity of treatment options due to the non-metastatic nature and rarity of desmoid tumors
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Utilization of radiation therapy post-surgically to prevent tumor recurrence
  • 5.2.2. Drug Type: Usage prescription drugs in desmoid tumors for targeted and sustained therapeutic interventions
  • 5.2.3. Tumor Location: Adoption of radiotherapy for extra-abdominal desmoid tumors due to their invasive nature
  • 5.2.4. End User: Increasing the preference for ambulatory surgical centers due to straightforward tumor resections
  • 5.2.5. Age Group: Rising desmoid tumors in adults due to age-related factors and comorbid conditions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Desmoid Tumors Market, by Treatment Type

• 6.1. Introduction
• 6.2. Anti-Hormonal Therapy
  • 6.2.1. Tamoxifen
  • 6.2.2. Toremifene
• 6.3. Chemotherapy
  • 6.3.1. Doxorubicin-based regimens
  • 6.3.2. Methotrexate and Vinblastine
  • 6.3.3. Pegylated liposomal doxorubicin
• 6.4. Cryoablation
• 6.5. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• 6.6. Radiation Therapy
• 6.7. Surgery
• 6.8. Targeted Therapy

7. Desmoid Tumors Market, by Drug Type

• 7.1. Introduction
• 7.2. OTC Drugs
• 7.3. Prescription Drugs

8. Desmoid Tumors Market, by Tumor Location

• 8.1. Introduction
• 8.2. Abdominal
• 8.3. Extra-Abdominal
• 8.4. Intra-Abdominal

9. Desmoid Tumors Market, by End User

• 9.1. Introduction
• 9.2. Ambulatory Surgical Centers
• 9.3. Hospitals
• 9.4. Specialty Clinics

10. Desmoid Tumors Market, by Age Group

• 10.1. Introduction
• 10.2. Adult
• 10.3. Geriatric
• 10.4. Pediatric

11. Americas Desmoid Tumors Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Desmoid Tumors Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Desmoid Tumors Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Novartis scemblix receives FDA priority review for advanced CML treatment
  • 14.3.2. Immunome acquires AL102 to enhance desmoid tumor treatment portfolio
  • 14.3.3. FDA approval of OGSIVEO enhances treatment options for desmoid tumors
  • 14.3.4. Ayala Pharmaceuticals and Biosight merge to enhance oncology focus and pipeline
  • 14.3.5. Iterion Therapeutics launches phase 1 trial of tegavivint for challenging lymphoma cases
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Novartis AG
  • 14.4.2. Bayer AG
  • 14.4.3. Immunome, Inc.
  • 14.4.4. SpringWorks Therapeutics

Companies Mentioned

• 1. Apotex Inc.
• 2. Baxter International, Inc
• 3. Bayer AG
• 4. Bristol-Myers Squibb Company
• 5. Cipla Limited
• 6. Dr Reddys Laboratories Limited
• 7. Encapsula NanoSciences LLC
• 8. Fermion Oy by Orion Corporation
• 9. Hetero Healthcare Limited.
• 10. Immunome, Inc.
• 11. Intelicure Lifesciences
• 12. Iterion Therapeutics
• 13. Johnson & Johnson Services, Inc.
• 14. Mayne Pharma Group Limited
• 15. Medichem, S.A.
• 16. Natco Pharma Limited
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. SpringWorks Therapeutics, Inc.
• 20. Sun Pharmaceutical Industries Limited
• 21. Synthon International Holding B.V.
• 22. Teva Pharmaceutical Industries Ltd